Dr. Fiona C. Killard-Lynch
Director of Research and Innovation, NIBRT
For patients with complex illnesses like cancer, autoimmune diseases, genetic disorders and neurodegenerative conditions, advanced therapies offer life-changing potential.
Advanced cellular therapies use living cells or genes to target and even cure diseases. A prime example is CAR-T cell therapy, where a patient’s immune cells are extracted, reengineered to better recognise and attack cancer cells, and then reintroduced into the body. Unlike traditional medicines, these therapies are designed to work with a patient’s unique biology.
Ireland falls short in cell and gene therapy investment
Globally, these therapies are transforming healthcare. In Ireland, however, access to such innovations is still limited. In 2022–2023, only 1.5% of the €2.6 billion invested in Ireland’s biopharma sector was directed toward cell and gene therapies. Without expanded clinical trials, specialised manufacturing facilities and stronger connections between research and clinical care, Ireland risks losing its competitive edge in this rapidly evolving field.
Ultimately, this means that Irish patients could face delayed access to innovative treatments, the financial burden of seeking care abroad or limited or no access to potentially life-saving therapies. There is hope, however, through IMPACT, a new all-Ireland research centre designed to position the country at the forefront of personalised advanced cellular therapeutics.
In 2022–2023, only 1.5% of the €2.6 billion
invested in Ireland’s biopharma sector was
directed toward cell and gene therapies.
Hub aims to advance precision healthcare
Supported by NIBRT, the cornerstone of Ireland’s biopharmaceutical training and research, IMPACT will create a national innovation hub to connect research institutes, hospitals, manufacturing facilities and industry partners. This collaboration will accelerate the clinical translation of new therapies, making them more accessible and affordable for patients. IMPACT’s personalised approach ensures that treatments are tailored to each patient’s individual biological profile.
This initiative aligns with both Ireland’s new Life Sciences Strategy and the European Commission’s push to strengthen biotechnology as a driver of competitiveness and strategic autonomy. With strong national support and partnerships across Europe, Ireland is well-positioned to lead in regenerative medicine and advanced therapeutics.
Strengthen Ireland’s position in advanced medicine
IMPACT’s mission is clear: improve patient access; reduce treatment costs; and strengthen Ireland’s healthcare ecosystem. By addressing these critical needs, Ireland can secure its place as a leader in regenerative medicine and precision healthcare.
